Catheter Precision, INC DEF 14A proxy statements

Catheter Precision, Inc. calls a Special Meeting to approve significant preferred stock issuances, an acquisition, and a reverse stock split to meet NYSE American listing requirements and fund operations.

Catheter Precision, Inc. will hold a special meeting to vote on increasing authorized common stock by 733% to facilitate urgent financing needed to fund operations beyond January 2026.

Catheter Precision announces a September 10th record date for its October 10th special meeting of stockholders to approve increasing authorized shares and ratify the auditor.

Catheter Precision, Inc. is seeking shareholder approval for significant capital structure adjustments, including the issuance of millions of shares related to warrants and convertible preferred stock, and a potential reverse stock split, at its upcoming 2025 Annual Meeting.

Catheter Precision, Inc. has scheduled its 2025 Annual Meeting of Stockholders to vote on key proposals including the election of a director, the issuance of over 13 million shares, and a reverse stock split.

Catheter Precision, Inc. has approved the issuance of a common stock purchase warrant to Ladenburg Thalmann & Co., Inc. as partial compensation for services related to its May 2025 PIPE financing, pending stockholder approval.

Catheter Precision, Inc. is calling an Annual Meeting to approve significant common stock issuances for warrant exercises and preferred stock conversion, alongside a reverse stock split to address NYSE American listing requirements, signaling ongoing financial challenges and a need for substantial capital.

Catheter Precision, Inc. (VTAK) has announced the appointment of Philip Anderson as its new Chief Financial Officer, effective immediately.

A proxy statement has been filed, outlining proposals for the upcoming annual meeting of shareholders.

Catheter Precision is holding a special meeting to seek stockholder approval for several key proposals, including the issuance of shares upon warrant exercise, an increase in authorized shares, and an amendment to the equity incentive plan.

A preliminary proxy statement has been filed, indicating upcoming corporate actions requiring shareholder votes.

A preliminary proxy statement has been filed, indicating upcoming corporate actions requiring shareholder votes.

Catheter Precision is asking stockholders to vote on several proposals at its upcoming annual meeting, including a reverse stock split, a reduction in authorized shares, and an amendment to the equity incentive plan.